SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MARZOLA, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.372
AS - Asia 2.765
EU - Europa 1.980
SA - Sud America 403
Continente sconosciuto - Info sul continente non disponibili 145
AF - Africa 84
OC - Oceania 10
Totale 11.759
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.129
SG - Singapore 1.056
IT - Italia 648
CN - Cina 621
VN - Vietnam 309
BR - Brasile 277
DE - Germania 266
HK - Hong Kong 216
GB - Regno Unito 199
PL - Polonia 165
UA - Ucraina 162
BD - Bangladesh 124
FI - Finlandia 116
TR - Turchia 112
CA - Canada 110
FR - Francia 105
SE - Svezia 77
RU - Federazione Russa 76
JP - Giappone 67
IN - India 60
ID - Indonesia 48
AR - Argentina 42
NL - Olanda 37
MX - Messico 36
ZA - Sudafrica 32
CO - Colombia 30
BE - Belgio 28
PK - Pakistan 21
IQ - Iraq 20
LT - Lituania 20
IL - Israele 18
ES - Italia 16
CR - Costa Rica 15
EC - Ecuador 15
SV - El Salvador 13
IR - Iran 12
NI - Nicaragua 12
SA - Arabia Saudita 12
AT - Austria 11
IE - Irlanda 11
MY - Malesia 11
PH - Filippine 11
SC - Seychelles 11
TT - Trinidad e Tobago 11
HN - Honduras 9
PR - Porto Rico 9
UY - Uruguay 9
CL - Cile 8
GP - Guadalupe 8
GT - Guatemala 8
TN - Tunisia 8
UZ - Uzbekistan 8
AU - Australia 7
DZ - Algeria 7
PY - Paraguay 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
CW - ???statistics.table.value.countryCode.CW??? 6
CZ - Repubblica Ceca 6
JM - Giamaica 6
JO - Giordania 6
MA - Marocco 6
AL - Albania 5
BG - Bulgaria 5
PE - Perù 5
RO - Romania 5
KE - Kenya 4
KZ - Kazakistan 4
TH - Thailandia 4
BO - Bolivia 3
CH - Svizzera 3
EE - Estonia 3
GR - Grecia 3
HU - Ungheria 3
KR - Corea 3
LB - Libano 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
AZ - Azerbaigian 2
DK - Danimarca 2
ET - Etiopia 2
HR - Croazia 2
NA - Namibia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
SN - Senegal 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
BZ - Belize 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
Totale 11.608
Salva come PNG Salva come JPEG
Città #
Ashburn 842
Singapore 683
San Jose 465
Fairfield 423
Woodbridge 405
Council Bluffs 249
Santa Clara 241
Ann Arbor 238
Beijing 234
Houston 226
Hong Kong 208
Seattle 187
Ferrara 169
Jacksonville 169
Chandler 166
Warsaw 159
New York 151
Cambridge 149
Wilmington 147
Los Angeles 108
Ho Chi Minh City 101
Dallas 91
Munich 89
Milan 86
Tokyo 66
Hanoi 63
Izmir 60
Princeton 53
Lauterbourg 50
Helsinki 48
Dearborn 47
Nanjing 47
Addison 44
Shanghai 40
San Diego 38
Jakarta 33
Rome 33
Toronto 33
The Dalles 32
Atlanta 31
Boardman 31
Bologna 31
São Paulo 31
Turku 31
London 30
Phoenix 28
Washington 28
Brussels 26
Frankfurt am Main 26
Montreal 26
Buffalo 24
Chicago 24
North Bergen 23
Orem 23
Brooklyn 22
Mexico City 22
Turin 22
Johannesburg 20
Falkenstein 19
Newark 19
Auburn Hills 16
Hefei 16
Redwood City 16
Charlotte 15
Denver 15
Manchester 15
Nanchang 15
Boston 14
Haiphong 14
Philadelphia 14
Naples 13
Bremen 12
San Francisco 12
San Mateo 12
Tianjin 12
Ferrara di Monte Baldo 11
Managua 11
Medellín 11
San José 11
San Salvador 11
Shenyang 11
Stockholm 11
Biên Hòa 10
Changsha 10
Da Nang 10
Dublin 10
Hebei 10
Lahore 10
Moscow 10
Mountain View 10
Bari 9
Chennai 9
Florence 9
Istanbul 9
Montevideo 9
Padova 9
Poplar 9
Bogotá 8
Guatemala City 8
Jinan 8
Totale 7.665
Salva come PNG Salva come JPEG
Nome #
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 325
Design and synthesis of99mTcN-labeled dextran-mannose derivatives for sentinel lymph node detection 320
Involvement of cell surface TG2 in the aggregation of K562 cells triggered by gluten 307
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 301
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 295
Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2 278
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 268
Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity 267
Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors 265
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 261
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 260
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 251
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 250
Physicochemical stability of cabazitaxel and docetaxel solutions 244
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 239
Pharmacological characterization of tachykinin tetrabranched derivatives 238
Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands 237
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 233
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 229
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 225
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 225
Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies 223
How terminal protection affects the chemical and biological properties of the antimicrobial calcitermin 223
Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors 221
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects 217
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 216
Structure-activity study at positions 3 and 4 of human neuropeptide S. 212
Novel Mixed NOP/Opioid Receptor Peptide Agonists 211
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 210
ANALOGHI DERMASEPTINICI AD ATTIVITA’ ANTIMICROBICA 208
Structure-activity studies on neuropeptide S - Identification of the amino acid residues crucial for receptor activation 207
Disordered Peptides Looking for Their Native Environment: Structural Basis of CB1 Endocannabinoid Receptor Binding to Pepcans 205
Synthesis of 2,6-Dimethyltyrosine-Like Amino Acids through Pinacolinamide-Enabled C-H Dimethylation of 4-Dibenzylamino Phenylalanine 202
Structure-activity relationship study on human urotensin II 201
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 197
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor 194
Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent in Vivo Activity 192
Thermodynamic and spectroscopic investigation on the role of Met residues in CuII binding to the non-octarepeat site of the human prion protein 187
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 187
Role of 2′,6′-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds 180
Synthesis and antimicrobial activity of dermaseptin S1 analogues 177
Impact of C- and N-terminal protection on the stability, metal chelation and antimicrobial properties of calcitermin 176
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 175
CCR4+ CD8+ T cells clonally expand to differentiated effectors in murine psoriasis and in human psoriatic arthritis 172
In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays 154
Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines 154
Manganese complexes for multimodal PET/MRI imaging: progress of METRICS project 147
The N-terminal domain of Helicobacter pylori's Hpn protein: The role of multiple histidine residues 143
Racemic synthesis and solid phase peptide synthesis application of the chimeric valine/leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid 141
Synthesis and characterization of manganese dithiocarbamate complexes: New evidence of dioxygen activation 135
Positively charged residues play a significant role in enhancing the antibacterial activity of calcitermin 129
METRICS project: Synthesis of Manganese Complexes as potential PET/MRI Agents 127
Synthesis and Pharmacological Characterization of Nociceptin/Orphanin FQ Dimeric Ligands 117
Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity 107
Production and Characterization of Semi-Solid Formulations for the Delivery of the Cosmetic Peptide Palmitoyl-GHK 104
null 94
null 42
Design of New Potent, Selective, and Long-Acting NOP Receptor Agonists through Multiple Sequential d-Amino Acid Substitutions of [Arg14 Lys15]N/OFQ(1-15)-NH2 36
Mapping the N/OFQ(1−13)-NH2 Address Domain to Identify G Protein-Biased NOP Receptor Agonists 18
Totale 11.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.279
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 679
Totale 52.958
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022425 0 0 0 0 33 14 35 37 37 51 55 163
2022/2023485 58 31 26 54 62 50 55 50 46 2 29 22
2023/2024396 31 41 26 10 16 90 17 46 10 11 18 80
2024/20251.453 35 29 146 62 175 142 28 71 255 129 188 193
2025/20264.337 460 158 329 481 624 322 532 229 352 456 246 148
2026/20271.547 160 220 411 545 211 0 0 0 0 0 0 0
Totale 11.759